Share on StockTwits

Investment Analysts’ ratings reiterations for Tuesday, August 5th:

ABIOMED (NASDAQ:ABMD) had its neutral rating reiterated by analysts at Zacks. The firm currently has a $27.00 target price on the stock. Zacks’ analyst wrote, “ABIOMED is a medical device company with a blue streak growth path. The company enjoys a strong demand for its Impella products. Multiple near-term drivers, including new products and clinical trials, should further boost the use of Impella. ABIOMED’s fiscal 2015-first quarter results were disappointing as it posted a loss of $0.04 per share and missed the Zacks Consensus Estimate of earnings of $0.02 per share. Increasing costs and expenses is a matter of concern as it drove the loss in the quarter and more than offset the impact of increased revenues. The company reiterated its revenues guidance between $205 and $212 million, an estimated rise of 12-15% over the prior fiscal year. As a result, we reiterate our Neutral recommendation with a price target of $27.00.”

Acxiom (NASDAQ:ACXM) had its market perform rating reaffirmed by analysts at BMO Capital Markets. They currently have a $20.00 price target on the stock, down from their previous price target of $25.00.

American International Group (NYSE:AIG) had its neutral rating reiterated by analysts at Zacks. They currently have a $55.00 target price on the stock.

Applied Micro Circuits (NASDAQ:AMCC) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $8.75 target price on the stock. Zacks’ analyst wrote, “Applied Micro reported disappointing first quarter fiscal 2015 results with a decrease in year-over-year earnings and revenues. We believe that Applied Micro is well positioned to grow its market share based on its diversified product offerings, such as X-Gene and X-Weave products. In addition, the company’s strong associations with renowned server OEMs are expected to augment its business going forward. However, the competitive strides in the industry are likely to have a detrimental impact on its businesses. Management is also concerned about the continued macroeconomic challenges. Nevertheless, we maintain our long-term Neutral recommendation for the stock. “

American Axle & Manufact. Holdings (NYSE:AXL) had its neutral rating reiterated by analysts at Zacks. They currently have a $19.00 price target on the stock. Zacks’ analyst wrote, “American Axle reported a 97% increase in earnings to $0.67 in second-quarter 2014, which missed the Zacks Consensus Estimate by $0.04. The year-over-year upside in profits was driven by strong sales and increased production volumes of products which support the North American light vehicle segment. Revenues went up 18.4% to $946.9 million, missing the Zacks Consensus Estimate of $982 million. American Axle is poised to benefit from a strong sales environment and product launches with the new advanced driveline technologies. Also, the product launches will diversify the company’s business and drive profits along with consistent free cash flow generation. However, pricing pressure by original equipment manufacturers remains a concern. Therefore, we have maintained a Neutral recommendation on AXL.”

Burger King Worldwide (NYSE:BKW) had its outperform rating reiterated by analysts at Zacks. The firm currently has a $32.00 price target on the stock. Zacks’ analyst wrote, “Burger King’s second-quarter earnings of $0.25 beat the Zacks Consensus Estimate by 8.7% and went up 19% year over year, mainly driven by lower operating costs and expenses. Total revenue dropped 6.1% year over year due to currency headwinds, adverse impact of refranchising the company-owned restaurants, and also missed the Zacks Consensus Estimate by 0.7%. Though franchising is currently hurting the revenues of the company, it will benefit over the long-term and will facilitate earnings and return on equity growth. Moreover, Burger King is transitioning its business model through product introductions, restaurant upgrades, proper marketing mix and improved operations. Exposure to faster-growing international markets is the key to Burger King’s expansion plans. Additionally, we are encouraged by its cost cutting initiatives, which are expected to boost bottom-line growth in the upcoming quarters. Thus, we maintain our Outperform recommendation on the shares. “

Borderfree (NASDAQ:BRDR) had its sector perform rating reiterated by analysts at RBC Capital. RBC Capital currently has a $17.00 price target on the stock.

Cardinal Health (NYSE:CAH) had its outperform rating reaffirmed by analysts at Credit Suisse. The firm currently has a $80.00 target price on the stock, up from their previous target price of $76.00.

Cardinal Health (NYSE:CAH) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $74.00 price target on the stock. Zacks’ analyst wrote, “Cardinal Health’s adjusted earnings of $0.83 for fiscal 2014-fourth-quarter rose 5.1% from $0.79 a year-ago and topped the Zacks Consensus Estimate by $0.02. However, revenues fell 9.9% to $22,894 million. Despite lower revenues, earnings rose due to lower operating expenses during the quarter. Performance in the Pharmaceutical segment continued to be disappointing due to the expiration of the contract with Walgreens. The company projects fiscal 2015 adjusted EPS to rise 6.8 to 12.0% over fiscal 2013 to $4.10 to $4.30. The company’s leverage position has also improved. As such, we maintain our Neutral recommendation and set a target price of $74.00.”

Cardinal Health (NYSE:CAH) had its overweight rating reiterated by analysts at Barclays. They currently have a $82.00 price target on the stock, up from their previous price target of $77.00.

Concur Technologies (NASDAQ:CNQR) had its underperform rating reissued by analysts at Stifel Nicolaus. The firm currently has a $72.00 price target on the stock, down from their previous price target of $73.00. The analysts wrote, “We believe the long-term opportunity is still ahead for CNQR as it attempts to create a truly comprehensive T&E platform. We are raising our FY15 and FY16 revenue but lowering our EPS estimates to reflect the more aggressive reinvestment profile. While valuation has moderated from earlier in the year, it still trades at a premium relative to other SaaS names that we find difficult to justify. Compared to CRM growing at a similar rate, CRM has been able to grow operating profit Y/Y despite a dilutive acquisition, while CNQR’s investment profile has been more aggressive, with operating profit declining. Due to increased margin investment, we are lowering our normalized operating margin to 18% (inline with our reduction in margin forecast). Applying a 45x P/E (CRM multiple at similar size and growth rate) on NTM earnings of $1.61 gives us a $72 PO. Reiterate Underperform.”

Community Health Systems (NYSE:CYH) had its neutral rating reaffirmed by analysts at Citigroup Inc.. They currently have a $54.00 target price on the stock, up from their previous target price of $40.00.

Community Health Systems (NYSE:CYH) had its outperform rating reissued by analysts at Credit Suisse. Credit Suisse currently has a $56.00 target price on the stock, up from their previous target price of $48.00.

Eastman Chemical Company (NYSE:EMN) had its neutral rating reissued by analysts at Zacks. They currently have a $83.00 price target on the stock.

Five9 (NASDAQ:FIVN) had its overweight rating reissued by analysts at Barclays. The firm currently has a $9.00 target price on the stock, down from their previous target price of $10.00.

Fluor Co. (NEW) (NYSE:FLR) had its neutral rating reissued by analysts at DA Davidson. They currently have a $82.00 price target on the stock, down from their previous price target of $85.00. The analysts wrote, “Fluor reported EPS of $1.02 for Q2 2014 from continuing operations compared to $0.98 per share in the prior year; above our estimate as indicated. Although revenue declined as expected, backlog improved from prior year levels and was up slightly from Q1. Management reiterated their guidance for earnings of $4.10-$4.45 per share this year.”

Henry Schein (NASDAQ:HSIC) had its neutral rating reiterated by analysts at Credit Suisse. Credit Suisse currently has a $121.00 target price on the stock, up from their previous target price of $120.00.

Incyte (NASDAQ:INCY) had its neutral rating reissued by analysts at Zacks. The firm currently has a $51.00 price target on the stock. Zacks’ analyst wrote, “Incyte reported a loss of $0.22 per share in the second quarter of 2014, wider than the Zacks Consensus Estimate of a loss of $0.09. The company reported earnings of $0.05 a year ago. The unfavorable results were due to higher expenses. Jakafi has performed well since its launch for MF and is expected to keep doing so going forward. We are encouraged by the company’s efforts to expand Jakafi’s label. The company’s deals with AstraZeneca and Bristol-Myers are also encouraging. Successful label expansion of the drug should drive growth further. Meanwhile, we are concerned about the company’s over-dependence on a single product for growth. We maintain our Neutral recommendation on the stock.”

Intel (NASDAQ:INTC) had its outperform rating reiterated by analysts at Zacks. The firm currently has a $41.00 price target on the stock. Zacks’ analyst wrote, “Intel is one of the leading producers of microprocessors in the world. The company’s second-quarter earnings exceeded the Zacks Consensus Estimate and forward guidance did not disappoint. Though Intel’s promise of success in the mobile segment is encouraging, this is likely to be mitigated by conservative spending by individuals and corporations, competition from ARM-based devices, and the impact of new product ramp-up costs (now pushed out to 2015). But its leading position in PCs, strength in servers, growing position in software and IoT segments and process lead leads us to reiterate our Outperform rating.”

Illinois Tool Works (NYSE:ITW) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $87.00 target price on the stock. Zacks’ analyst wrote, “Illinois Tool Works’ second-quarter 2014 earnings increased 31.5% year to year to $1.21 per share, surpassing the Zacks Consensus Estimate of $1.20. Shares buyback associated with the divestiture of the Industrial Packaging business boosted earnings growth. Revenues climbed 3.5% on the back of 1.4% organic growth. Of segments, Automotive OEM, Test & Measurement and Electronics, Food Equipment and Specialty Products performed well. Operating margin went up 300 basis points (bps), including 120 bps contribution from enterprise strategies. For 2014, management increased its earnings guidance to the range of $4.50-$4.62 per share while total revenue growth is predicted within 3-4%. Considering all these factors, we currently maintain a Neutral recommendation on the stock.”

Michael Kors Holdings (NASDAQ:KORS) had its underweight rating reissued by analysts at Barclays. Barclays currently has a $78.00 price target on the stock, down from their previous price target of $82.00.

Michael Kors Holdings (NASDAQ:KORS) had its neutral rating reiterated by analysts at Citigroup Inc.. Citigroup Inc. currently has a $87.00 target price on the stock, down from their previous target price of $98.00.

Loews Corp. (NYSE:L) had its underperform rating reaffirmed by analysts at Zacks. They currently have a $38.00 price target on the stock. Zacks’ analyst wrote, “Loews in the second quarter surpassed the Zacks Consensus Estimate as well as year ago earnings. The quarter witnessed higher earnings at CNA Financial and higher parent company investment income driven by improved performance of the trading portfolio. However, lower earnings at Diamond Offshore limited the upside. The top line slid on lower insurance premiums and lower contract drilling revenues. Expenses decreased due to lower Insurance claims & policyholders’ benefits. Loews remains on track to strengthen its hotel business by doubling its hotel count within the next two to four years and expects to triple its net income by 2015. Though Diamond Offshore continues to improve its fleet, a weakening ultra-deepwater and deepwater market will dampen results. Boardwalk remains on track to expand existing pipeline infrastructure as market condition improves. The acquisitions of HP Storage and Louisiana Midstream support its strategy to focus on diversification, to become less dependent on its base gas transportation business. A strong balance sheet with low leverage and adequate cash and strong rating scores are among the positives. “

MFA Financial (NYSE:MFA) had its hold rating reiterated by analysts at Wunderlich. They currently have a $9.00 target price on the stock, up from their previous target price of $8.00. The analysts wrote, “Hold-rated MFA Financial (MFA) reported 2Q14 EPS of $0.20, in-line with dividends and our estimate. BVPS increased Q/Q to $8.37. MFA is levered to improving credit; the legacy non-agency bonds it purchased (on average) 8 years ago at a discount currently represent about 80% LTV, as principal has been paid down and home prices have appreciated. The very factors that contribute to higher fair market value of its portfolio price MFA out of the market on the margin. The company is venturing into other credit sensitive MBS, but issuance and trading volumes are limited. As we roll out our estimates through 2015, we are increasing our target by $1/sh to $9. This is roughly in-line with forward BVPS, and is consistent with the peer group valuation. Maintain Hold.”

Ocwen Financial Corp (NYSE:OCN) had its buy rating reiterated by analysts at Bank of America. They currently have a $35.00 price target on the stock, down from their previous price target of $54.00. The analysts wrote, “OCN is a leading independent mortgage servicer specializing in distressed loans. We think it is well positioned to capitalize on trends within the servicing arena as the industry digests a backlog of distressed loans generated at the peak of the real estate cycle and transitions to a less bank-centric structure. Investors could also benefit from a potential transformation to a less capital-intense servicer model.”

Owens-Illinois (NYSE:OI) had its neutral rating reissued by analysts at Citigroup Inc.. The firm currently has a $35.00 target price on the stock, down from their previous target price of $36.00.

PBF Logistics (NASDAQ:PBFX) had its buy rating reaffirmed by analysts at Citigroup Inc.. They currently have a $29.50 price target on the stock, down from their previous price target of $31.00.

Plum Creek Timber Co. (NYSE:PCL) had its buy rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $48.00 target price on the stock, down from their previous target price of $50.00.

The Procter & Gamble Company (NYSE:PG) had its neutral rating reaffirmed by analysts at Zacks. They currently have a $83.00 target price on the stock. Zacks’ analyst wrote, “P&G reported mixed fiscal third-quarter 2014 results, beating the Zacks Consensus Estimate for earnings but missing the same for sales. Earnings grew 20% year over year driven by pricing gains, cost reductions and lower taxes. Organic revenues were up 2% as better pricing made up for softer volumes. Overall, we are encouraged by P&G’s strong brand recognition, diversified portfolio, rapid growth in developing nations, impressive product development capabilities and marketing prowess. The company’s plan to divest around 100 underperforming brands so as to concentrate better on fewer core strategic brands sounds encouraging. However, currency headwinds, rising commodity costs, increasing competitive pressures, challenging consumer spending environment in the U.S. and deceleration in emerging market growth rates remain the overhangs. Also, we would like to see significant margin improvement before becoming more positive on the stock.”

Qiagen NV (NASDAQ:QGEN) had its equal weight rating reiterated by analysts at Barclays. The firm currently has a $24.00 target price on the stock, up from their previous target price of $19.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) had its buy rating reissued by analysts at Deutsche Bank. Deutsche Bank currently has a $425.00 price target on the stock, up from their previous price target of $410.00.

RetailMeNot (NASDAQ:SALE) had its neutral rating reiterated by analysts at Credit Suisse. Credit Suisse currently has a $32.00 price target on the stock, down from their previous price target of $43.00.

Sealed Air Corp (NYSE:SEE) had its neutral rating reaffirmed by analysts at Citigroup Inc.. Citigroup Inc. currently has a $33.00 price target on the stock, down from their previous price target of $35.00.

Swift Energy Company (NYSE:SFY) had its underweight rating reaffirmed by analysts at Barclays. Barclays currently has a $10.00 price target on the stock, down from their previous price target of $11.00.

Spirit AeroSystems Holdings (NYSE:SPR) had its neutral rating reiterated by analysts at Credit Suisse. They currently have a $43.00 target price on the stock, up from their previous target price of $31.00.

SunPower (NASDAQ:SPWR) had its neutral rating reiterated by analysts at Zacks. Zacks currently has a $36.00 target price on the stock. Zacks’ analyst wrote, “In second-quarter 2014, SunPower Corporation’s earnings per share missed the Zacks Consensus Estimate and decreased from the year ago figure, primarily due to lower revenues from Americas and Europe, the Middle East and Africa. Again, increasing competition in solar industry are matters of concern. However, higher demand for solar products from China and Japan is expected to play a vital role for the company’s upcoming performance, as it has significant presence in both the nations. In addition, SunPower’s stable liquidity position, cost-control initiatives and strong project pipeline will likely boost its future cash inflow. The company’s strategic asset acquisition program and increasing production capacity will enable it to meet increasing customer demand. We are maintaining our Neutral recommendation on the company. “

Thor Industries (NYSE:THO) had its outperform rating reissued by analysts at BMO Capital Markets. They currently have a $64.00 price target on the stock, down from their previous price target of $72.00.

Teekay (NYSE:TK) had its overweight rating reiterated by analysts at Barclays. Barclays currently has a $70.00 price target on the stock, up from their previous price target of $65.00.

Toyota Motor Corp (NYSE:TM) had its neutral rating reissued by analysts at Zacks. Zacks currently has a $124.00 target price on the stock. Zacks’ analyst wrote, “Toyota posted earnings of 185.34 per share ($3.64 per ADR) in first-quarter fiscal 2015, surpassing the Zacks Consensus Estimate of $3.07. Consolidated revenues increased 2.2% year over year to 6.39 trillion ($62.65 billion), missing the Zacks Consensus Estimate of $62.87 billion. The weak fiscal 2015 guidance and a string of product recalls are some headwinds for the stock. However, there are numerous positives, including its leading position in terms of global vehicle sales, product development, capacity increase, emerging markets expansion and the new share repurchase program. Moreover, Toyota plays a pivotal role in the global market for environment-friendly vehicles. “

TriNet Group (NASDAQ:TNET) had its buy rating reaffirmed by analysts at Deutsche Bank. Deutsche Bank currently has a $24.00 target price on the stock, down from their previous target price of $27.00.

Tessera Technologies (NASDAQ:TSRA) had its buy rating reaffirmed by analysts at S&P Equity Research. They currently have a $33.00 price target on the stock, up from their previous price target of $28.00. The analysts wrote, “TSRA reported June quarter (F2Q14) revenue/non-GAAP EPS of $37M/$0.19higher than our estimate of $32M/$0.05 with the earnings upside primarily driven by top-line and good expense control. Recurring revenues were about $35.8M in the June quarter (our estimate $32M) and episodic revenues were $1.4M. We had no episodic revenues in our June forecast. “The episodic revenues (non-recurring revs, back payments, etc) are difficult to forecast. The September quarter revenue guidance of $92-$94M was above our forecast of $82M (including episodic revenues of $50M). More importantly, the recurring revenue outlook for FY14 was raised to $140M (from $120M) and FY15 was increased to $195M (from $150M) as the recent agreement with Micron gets rolled into the forecast.The earnings power based on the recurring revenue basis alone could be close to $1.00 next year. We reiterate Buy rating as we believe TSRA’s products are well-positioned and the restructuring story is shaping up well.”

Tessera Technologies (NASDAQ:TSRA) had its neutral rating reiterated by analysts at Zacks. Zacks currently has a $27.00 price target on the stock. Zacks’ analyst wrote, “Tessera is a provider of back-end technology for semiconductor manufacturing. The company’s second quarter earnings exceeded the Zacks Consensus Estimate. Management also provided an encouraging guidance. Management is refocusing the business on the higher-margin, higher-risk licensing model, so the host of patents, new technologies and customer wins are encouraging. The product portfolio has also been revamped to target the mobile segment, which should help growth. The major negative is the excessive legal charges, which are necessary to protect its IP. This is a special concern given Tessera’s small size with respect to defaulters that are usually big technology companies such as Micron. However, its prospects appear to be improving, and therefore we have a Neutral recommendation on TSRA shares.”

Wesco Aircraft Holdings (NASDAQ:WAIR) had its buy rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $26.00 price target on the stock, down from their previous price target of $28.00.

Wesco Aircraft Holdings (NASDAQ:WAIR) had its overweight rating reaffirmed by analysts at Barclays. The firm currently has a $24.00 target price on the stock, down from their previous target price of $25.00.

Whole Foods Market (NYSE:WFM) had its neutral rating reiterated by analysts at Zacks. Zacks currently has a $40.00 price target on the stock.

Exelis (NYSE:XLS) had its neutral rating reiterated by analysts at Credit Suisse. They currently have a $20.00 price target on the stock, up from their previous price target of $19.00.

Receive News & Ratings for ABIOMED Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.